Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has become a trend in managing Type 2 diabetes and obesity. Med spas, aesthetics and wellness practices, women’s clinics and primary care clinics are prescribing semaglutide medications for those who struggle with obesity or are impacted by type 2 diabetes. The well-known brands like Wegovy and Ozempic reshaped the approach to weight loss and insulin regulation, which created an uptick in interest within M&A. 

JP Morgan projects the global semaglutide market to grow to $71 billion by 2032. Due to current surges in revenue and increased investments in the space, buyers and sellers project clinics with semaglutide offerings to have a higher rate of return and profits. This article delves into the mechanisms of semaglutide, its commercial impact and how these trends influence M&A activities.

What is Semaglutide?

Semaglutide is a synthetic GLP-1 receptor agonist that mimics the natural incretin hormone. Incretins are responsible for stimulating insulin secretion in response to food intake.

Semaglutide works by:

• Enhancing Insulin Secretion: In response to elevated blood glucose levels, semaglutide amplifies insulin release
• Reducing Appetite: It slows gastric emptying and acts on brain centers to suppress hunger, making it highly effective for weight management
• Lowering Blood Sugar: By reducing glucagon secretion and improving glycemic control

The efficacy of semaglutide has positioned it as a revolutionary drug, addressing both diabetes and obesity — two of the most significant public health challenges globally.

What are Ozempic and Wegovy? 

Ozempic

Ozempic is the most well-known GLP-1, as it has shown superior efficacy compared to traditional medications like Metformin and Sulfonylureas. Metformin is the medication traditionally used for managing type 2 diabetes, and is considered a biguanide by improving the body’s response to insulin. Sulfonylureas stimulates the pancreas to release more insulin, which lowers blood sugar levels. Before the advent of GLP-1 receptor antagonists, these medications were the primary response to diabetic or pre-diabetic conditions. Approved by the FDA in 2017, Ozempic, administered as a weekly subcutaneous injection, offers glycemic control and cardiovascular benefits, reducing the risk of major adverse cardiac events and is proven more effective than Metformin and Sulfonylureas. 

Wegovy

In competition with Ozempic, Wegovy was launched in 2021. Wegovy targets obese and overweight individuals with comorbidities. It delivers a higher dose of semaglutide than Ozempic. Clinical trials demonstrated an average weight reduction of 15-20% over 68 weeks, a breakthrough compared to older weight-loss drugs.

Market Growth

The soaring demand for semaglutide has triggered a wave of M&A activities, driven by strategic acquisitions, collaborative partnerships and vertical integration. 

Strategic Acquisitions

Strategic partnerships between MSOs and aesthetics and wellness practices enable faster innovation. Clinics without MSO backing often sometimes struggle to implement the newest technology at a practical price. MSOs step in and provide the financial backing for these clinics to invest in the newest innovations, often streamlining processes for healthcare. MSOs can also help with establishing or increasing effective marketing, managing costs, and scaling the clinics. 

MSOs and individual clinicians are acquiring startups and mid-sized wellness practices specializing in GLP-1 therapies or complementary technologies. For instance:

• MSO Buyers: MSOs are investing in companies that provide semaglutide services by investing through majority or minority ownership in the clinics. They provide non-clinical services such as marketing, HR, updates to the equipment and procurement details. MSOs can provide benefits such as recruitment and training of staff, managing billing and financial reports and are able to negotiate contracts with suppliers for lower rates. MSO deal structures vary widely, and can provide benefits tailored to your values
• Individual Buyers: While MSOs can provide ample support, there also are numerous benefits to selling to another individual. If you are a seller that values cultural continuity, is planning on retiring, or prefers selling to a personal connection, an individual buyer might be right for you 

Unique MSO deal structures can offer you an exit strategy that allows you to transition into a more comfortable role, where an individual buyer can ensure your company culture stays consistent post-sale. If you’re considering selling to an MSO or individual buyer, think about your goals and what you want for the future of your business.

The Future of Semaglutide and M&A

Expanding Indications

With the recent uptick in semaglutide, an already $20 billion industry is projected to nearly triple in revenue in the next 10 years. One of the most significant drivers of this investment is the global increase in obesity and type 2 diabetes. The advent of semaglutide and its competitors allows medications to reach those who were originally left undiagnosed and untreated. With a simple injection once a week, semaglutide offers a bright future for those who struggle with weight or diabetic-related conditions.

Research into semaglutide’s potential extends beyond diabetes and obesity. Trials are exploring its efficacy in:

• Non-alcoholic Steatohepatitis (NASH): A chronic liver condition linked to obesity
• Cardiovascular Disease: Enhancing its already proven benefits
• Neurodegenerative Disorders: Preliminary studies suggest benefits in Alzheimer’s disease

Expanding indications could further drive wellness M&A activity as companies position themselves to capture new markets.

Semaglutide investments within current clinics can increase the valuation and overall health of the clinics, priming them for an equity-based partnership with an MSO or an eager individual buyer looking to take over a lucrative practice. 

Conclusion

Semaglutide’s journey from a groundbreaking diabetes drug to a multi-indication blockbuster underscores its transformative impact on healthcare. The rise of at-home semaglutide companies and heightened M&A activity reflect the dynamism of this market. As MSOs and aesthetics and wellness clinics converge, the future promises innovation, expanded access and continued growth.

Reach out to our wellness brokerage experts at LuxMed to explore what your clinic is valued at.